You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Automated Intestinal Electrical Stimulation for Diabetes
SBC: TRANSTIMULATION RESEARCH INC Topic: 200Diabetes affects more than 9% of Americans and costs over $300 billion in 2017 in USA. Medical therapies have limitations in treating diabetic patients with obesity due their common side effects of weight gain. Bariatric surgery has been proposed for treating diabetic patients with promising outcomes. In this project, we propose a novel method of intestinal electrical stimulation (IES) for treatin ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
Automated, portable, concurrent, WMD detection system
SBC: Concurrent Analytical, Inc. Topic: N/ADESCRIPTION (provided by applicant): The overall goal of this project is the development of a fully automated, wireless ethernet capable, near realtime, field deployable immunoassay-based analysis system for the concurrent, ultra low-level detection of biowarfare agents in air or water by using innovations in surface enhanced Raman scattering (SERS) and related supporting materials and hardware. A ...
STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health -
Automated Rodent Research Home Cage Monitoring System for Animal Welfare
SBC: TRICORDER ARRAY TECHNOLOGIES LLC Topic: 100PROJECT SUMMARY The for profit small business concernTricorder Array Technologies LLCwill developin partnership with the University of Alabama at BirminghamSIDECAReSensing and Integrating Data for Environmental Conditions in Animal ResearchThis device will automate collection of relevant data that will enhance consistency in animal models used to study human health treatment researchOur innovative ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Biodegradability and Biocompatibility of a Shape Memory Polymer Wrap to Improve Saphenous Vein Graft Patency in Peripheral and Coronary Artery Bypass Grafting Surgeries
SBC: VenoStent, Inc. Topic: NHLBIPROJECT SUMMARY/ABSTRACT Peripheral artery disease (PAD) affects nearly 12 million people in the United States. One of the most common surgical therapies is peripheral artery bypass grafting (PABG). Some patients are eligible for less invasive treatment options like angioplasty, but patients with calcified lesions are not. In patients that do receive PABG, approximately 20% fail within the first y ...
STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health -
BIONIC BAROREFLEX SYSTEM FOR BLOOD PRESSURE CONTROL
SBC: TK TX COMPANY Topic: N/APatients with multiple system atrophy (MSA), a sporadic and progressive neurodegenerative disorder, suffer from orthostatic hypotension, postprandial hypotension and supine hypertension. Hypotension causes presyncopal symptoms usually within seconds of standing and requires the patient to sit or lie down to prevent syncope. Supine hypertension reduces leep quality through excessive nocturnal diur ...
STTR Phase I 2002 Department of Health and Human ServicesNational Institutes of Health -
Bitter Human Taste Bud Epithelial Cell Platforms for Bitter Taste Antagonist Discovery
SBC: DISCOVERYBIOMED, INC. Topic: NIDCDPrincipal Investigators for Small BusinessDiscoveryBioMedIncDBMand Monell Chemical Senses Center Project Summary Abstract Bitter taste in foods and medicines presents a barrier to overcoming global public health challengesfood insecuritypoor nutritional healthand poor compliance with medication useparticularly among children and the elderlySugar and saltthe mainstays to address these challengesfur ...
STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health -
Broad Spectrum Bitter Taste Antagonists Discovery
SBC: DISCOVERYBIOMED, INC. Topic: NIDCDPrincipal Investigators for Small Business: DiscoveryBioMed, Inc. (DBM) and Monell Chemical Senses Center Project Summary Abstract Bitter taste in foods and medicines presents a barrier to overcoming global public health challenges: food insecurity, poor nutritional health, and poor compliance with medication use, particularly among children and the elderly. Sugar and salt, the mainstays to addres ...
STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health -
Cancer dual-targeting of an infectivity-enchanced CRAd
SBC: VECTORLOGICS, INC. Topic: N/ADESCRIPTION (provided by applicant): A number of characteristics of the Adenovirus type 5 (Ad5) make it an optimal gene therapy/virotherapy vector suitable for a wide array of cancer therapeutic approaches. Despite these advantages, overall ifficacy remains limited by sub-optimal adenovirus delivery to cancer tissues. One conceptual approach to overcome this limitation is to achieve an amplificati ...
STTR Phase I 2006 Department of Health and Human ServicesNational Institutes of Health -
Cancer dual-targeting of an infectivity-enhance CRAd
SBC: VECTORLOGICS, INC. Topic: N/ADESCRIPTION (provided by applicant): Studies of the molecular mechanisms underlying neoplastic transformation and progression have resulted in the understanding that cancer is a genetic disease, deriving from the accumulation of a series of acquired genet ic lesions. Despite advances in chemotherapy, radiation delivery, and surgical treatment regimens, survival from many advanced cancers remains ...
STTR Phase II 2008 Department of Health and Human ServicesNational Institutes of Health -
Cardiac Interactions of New Adriamycin Analogs and Taxol
SBC: GEM Pharmaceuticals Topic: N/ADESCRIPTION (provided by applicant): Paclitaxel (Taxol) and doxorubicin (DOX, Adriamycin) are chemotherapeutic drugs used in treatment of metastatic breast cancer. When used individually, they produce a 30-40 percent response rate. When combined, using high doses of DOX (450-550 mg/m2), the response rate is increased to 85-95 percent. This represents a significant improvement in tumor responsivene ...
STTR Phase I 2004 Department of Health and Human ServicesNational Institutes of Health